Cannabinoid Based
Anti-Viral Treatments
to [Re-Empower Your Quality of Life]
What Is Our Vision?
Andromeda Life Sciences brings a wealth of industry experience in pioneering cannabinoid-based treatments for long Covid, neurological conditions, and oncology challenges. Our focus on cutting-edge research and commitment to improving quality of life sets us apart.
Why We Care
Persistent Challenge: Despite vaccination efforts, COVID-19 cases expected to rise for years due to emerging mutant strains.
Global Impact: Since late 2019, COVID-19 led to multiple pandemics, causing respiratory and neurological issues, as well as long COVID sequelae.
Enduring Reality: UK Health Minister emphasizes the need to adapt and live with COVID-19 akin to seasonal flu.
Investment Opportunity: Addressing the long-term health impacts of COVID-19 presents a significant opportunity for innovative biotech solutions.
Unveiling Long COVID: A Growing Concern
Global Impact: Approximately 100 million individuals worldwide are affected by long COVID, with neurological symptoms prevailing.
Neurological Focus: Long COVID primarily manifests as memory and cognitive disturbances, significantly impacting work and daily life.
Demographic Shift: Young adults (30-45) are increasingly affected, particularly by the Omicron variant, which has been very virilent since spring 2022.
Persistent Challenge: Emerging evidence indicates higher incidence and longer-lasting effects of long COVID than initially anticipated.
Widespread Impact: The Omicron variant challenges the notion that only the elderly are susceptible, affecting even the young, fit, and vaccinated populations.
Investment in solutions for understanding and treating long COVID is crucial in addressing this evolving health challenge.
Catastrophic Long COVID: A Looming Crisis
UK Snapshot: With 2.5 million reported long COVID cases, Andromeda’s propriety research estimates 10% (250k) of these cases are truly Catastrophic Long COVID cases.
Severe Cognitive Impact: Catastrophic Long COVID patients face debilitating cognitive issues, often struggling with basic daily tasks like food and laundry due to extensive brain fog.
Workforce Disruption: Virtually all sufferers are unable to work, confined to their homes, representing the true casualties of long COVID.
Economic Implications: The financial burden of caring for these individuals will be substantial, necessitating urgent investment in solutions.
Investing in research and support for Catastrophic Long COVID cases is imperative to mitigate its devastating effects on individuals and economies worldwide.
The Economic Toll of Long COVID
Scale of the Crisis: With 100 million victims and long COVID cases at least 10 times the death rate, the true economic toll could be significantly higher.
Global Healthcare Burden: Long COVID imposes staggering costs, reaching £500 billion globally. Each patient racks up £5,000 monthly for medical expenses, totaling £150,000 over a year. Additional expenses for social services escalate the economic impact further.
Lost Revenue: Non-working patients contribute no taxes, exacerbating the financial strain on governments.
Indirect Family Impact: Families supporting loved ones with long COVID face additional financial and emotional strain, further highlighting the broader societal ramifications of this chronic debilitating condition.
Investment in research, treatment, and support services is essential to mitigate the escalating economic burden of long COVID on global healthcare systems.
Addressing Twin Health Challenges
Mitigating Infection Impact:
• Vaccination initiatives
• Advancements in medical treatments
• Health education programs targeting factors like obesity
• Providing medical support for Long COVID sufferers
Focusing on Young Long COVID Patients:
• Tailored support and treatment for the symptomology of young long COVID patients
Governments must prioritize strategies to both reduce the severity of infection impacts and address the unique needs of young long COVID patients to effectively combat these twin long-term health challenges.
Why We Care
UK Snapshot: With 2.5 million reported long COVID cases, Andromeda’s propriety research estimates 10% (250k) of these cases are truly Catastrophic Long COVID cases.
Severe Cognitive Impact: Catastrophic Long COVID patients face debilitating cognitive issues, often struggling with basic daily tasks like food and laundry due to extensive brain fog.
Workforce Disruption: Virtually all sufferers are unable to work, confined to their homes, representing the true casualties of long COVID.
Economic Implications: The financial burden of caring for these individuals will be substantial, necessitating urgent investment in solutions.
Investing in research and support for Catastrophic Long COVID cases is imperative to mitigate its devastating effects on individuals and economies worldwide.
Unveiling Long COVID: A Growing Concern
Global Impact: Approximately 100 million individuals worldwide are affected by long COVID, with neurological symptoms prevailing.
Neurological Focus: Long COVID primarily manifests as memory and cognitive disturbances, significantly impacting work and daily life.
Demographic Shift: Young adults (30-45) are increasingly affected, particularly by the Omicron variant, with cases emerging since spring 2023.
Persistent Challenge: Emerging evidence indicates higher incidence and longer-lasting effects of long COVID than initially anticipated.
Widespread Impact: The Omicron variant challenges the notion that only the elderly are susceptible, affecting even the young, fit, and vaccinated populations.
Investment in solutions for understanding and treating long COVID is crucial in addressing this evolving health challenge.
Catastrophic Long COVID: A Looming Crisis
UK Snapshot: With 2.5 million reported long COVID cases, Andromeda estimates 10% (250k) are Catastrophic Long COVID cases.
Severe Cognitive Impact: Catastrophic Long COVID patients face debilitating cognitive issues, often struggling with basic daily tasks like food and laundry due to extensive brain fog.
Workforce Disruption: Virtually all sufferers are unable to work, confined to their homes, representing the true casualties of long COVID.
Economic Implications: The financial burden of caring for these individuals will be substantial, necessitating urgent investment in solutions.
Investing in research and support for Catastrophic Long COVID cases is imperative to mitigate its devastating effects on individuals and economies worldwide.
The Economic Toll of Long COVID
Scale of the Crisis: With 100 million victims and long COVID cases at least 10 times the death rate, the true economic toll could be significantly higher.
Global Healthcare Burden: Long COVID imposes staggering costs, reaching £500 billion globally. Each patient racks up £5,000 monthly for medical expenses, totaling £150,000 over a year. Additional expenses for social services escalate the economic impact further.
Lost Revenue: Non-working patients contribute no taxes, exacerbating the financial strain on governments.
Indirect Family Impact: Families supporting loved ones with long COVID face additional financial and emotional strain, further highlighting the broader societal ramifications of this chronic debilitating condition.
Investment in research, treatment, and support services is essential to mitigate the escalating economic burden of long COVID on global healthcare systems.
Addressing Twin Health Challenges
Mitigating Infection Impact:
• Vaccination initiatives
• Advancements in medical treatments
• Health education programs targeting factors like obesity
• Providing medical support for Long COVID sufferers
Focusing on Young Long COVID Patients:
• Tailored support and treatment for the symptomology of young long COVID patients
Governments must prioritize strategies to both reduce the severity of infection impacts and address the unique needs of young long COVID patients to effectively combat these twin long-term health challenges.
What We Offer
Andromeda presents a potential ground-breaking therapeutic solution for long COVID based on highly promising preliminary clinical trials.
Discover our cutting-edge treatments for complex health challenges
Cannabinoid Treatments
Neurological Solutions
What Our Clinical Studies Show
We are currently working with over 30 patients in Switzerland, Germany, UK and Ireland who have demonstrable Long Covid disease:
Of those, the majority are showing excellent clinical progress, with only seven having made little progress so far.
Based on a Andromeda's use of -additional cannabinoid components:
We have observed an improvement of a number of neurological symptoms such as loss of smell and cognitive function.
What Our Clinical Studies Show
We are currently working with over 30 patients in Switzerland, Germany, UK and Ireland who have demonstrable Long Covid disease:
Of those, the majority are showing excellent clinical progress, with only seven having made little progress so far.
Based on a Andromeda's use of -additional cannabinoid components:
Of those, the majority are showing excellent clinical progress, with only seven having made little progress so far.
What Is Our Intellectual Property?
USPTO Filing
• Nov 2018 application number 62/929,029 involving the use cannabinoids with dramatic improvement in cognitive functions
• March 26th 2020 application number 63/000,032 to establish priority
• “Cannabinoid-based composition for mitigation of viral effects”
• Patent updated in the statutory time period and renewed March 25th 2021
• Unique formulation
• CBD, CBG, Zinc and important terpenes
• Oral administration
Who We Are
Dr. Med. Gottfried Sodeck
Chairman of the Board
Gottfried is Assistant Professor of Internal Medicine with several subspecialty trainings and an active, forward looking entrepreneur. He holds active medical licenses to practice in EMEA and UK/ Commonwealth.
Dr. H. Peter Black
Chief Medical Officer
After studying science, and also law, Dr. Black began his medical studies and graduated from McGill University, Montreal, Canada, with an MD CM. degree, then completing his post graduate work in radiology and neuro radiology and neurology, both in Canada and in the United States.
Dr. H. Peter Black
Chief Medical Officer
After studying science, and also law, Dr. Black began his medical studies and graduated from McGill University, Montreal, Canada, with an MD CM. degree, then completing his post graduate work in radiology and neuro radiology and neurology, both in Canada and in the United States.
Steven Splinter, PhD
Chief Scientist (Non-Medical)
Steven is an expert in interfacial phenomena, having earned a Ph.D. in Engineering Science in 1994. He has authored or co-authored numerous scientific publications and patents and has been invited as a speaker at international science conferences.
Adrian Marshall
Board Member
Adrian Marshall was the founder and CEO of Nicoventures Ltd, the BAT group owned consumer healthcare products company that successfully secured Marketing Authorisation for VOKETTM, the world's first nicotine aerosol inhaler to be licensed by a national medicines agency (UKMHRA) as a "safer alternative to smoking".
Adrian Marshall
Board Member
Adrian Marshall was the founder and CEO of Nicoventures Ltd, the BAT group owned consumer healthcare products company that successfully secured Marketing Authorisation for VOKETTM, the world's first nicotine aerosol inhaler to be licensed by a national medicines agency (UKMHRA) as a "safer alternative to smoking".
Seema Gupta
Board Member
Seema is a seasoned professional with over 25 years of experience in business development and finance, primarily within the UK healthcare sector. With a Diploma in Practice Management from AMSPAR and a Bachelor's degree from the University of Lucknow India, her career spans launching businesses, excelling as Sales Director in the construction industry since Apr 2016, and a significant tenure in finance at DMC Healthcare from 2002 to 2011.
Kassem Sobh
Board Member
Born to Lebanese parents in Jeddah, Saudi Arabia, Kassem moved to Montreal, Canada for his post-secondary studies where he graduated from McGill University and Concordia University with degrees in Biochemistry and Computer Science.
Kassem Sobh
Board Member
Born to Lebanese parents in Jeddah, Saudi Arabia, Kassem moved to Montreal, Canada for his post-secondary studies where he graduated from McGill University and Concordia University with degrees in Biochemistry and Computer Science.
Team Members
Daz Baldwin
Dr. Gordon Balazsi MD
John Cronin
Cressida Rabela
COO
Scientific Advisory Panel Lead
Intellectual Property Collaborator
Government Relations/Medical
Team Members
Daz Baldwin
COO
Dr. Gordon Balazsi MD
Scientific Advisory Panel Lead
John Cronin
Intellectual Property Collaborator